Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2011

Rajeshkumar N V, De Oliveira Elizabeth, Ottenhof Niki, Watters James, Brooks David, Demuth Tim, Shumway Stuart D, Mizuarai Shinji, Hirai Hiroshi, Maitra Anirban, Hidalgo Manuel

Abstract excerpt

PURPOSE: Investigate the efficacy and pharmacodynamic effects of MK-1775, a potent Wee1 inhibitor, in both monotherapy and in combination with gemcitabine (GEM) using a panel of p53-deficient and p53 wild-type human pancreatic cancer xenografts. EXPERIMENTAL DESIGN: Nine individual patient-derived pancreatic cancer xenografts (6 with p53-deficient and 3 with p53 wild-type status) from the PancXenoBank collection...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Gemcitabine

Share to Pyrazoles

Share to Pyrimidinones

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 21389100
DOI: 10.1158/1078-0432.CCR-10-2580
PMCID: PMC3307341

Genes

GEM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.PMID 21389100Read ↗

WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.Semantic proximity Read ↗

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancerSemantic proximity Read ↗

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancerSemantic proximity Read ↗

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agentsSemantic proximity Read ↗

Molecular Pathways: Targeting the Protein Kinase Wee1 in CancerSemantic proximity Read ↗

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.Semantic proximity Read ↗

Wee1 kinase as a target for cancer therapySemantic proximity Read ↗

MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma CellsSemantic proximity Read ↗

Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancerSemantic proximity Read ↗

Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.Semantic proximity Read ↗

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitorSemantic proximity Read ↗

Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.